Payment overview · 2025
General Payments
$821.26
44 reported records · 18 companies
Healthcare provider profile · identity verified
Ghulam Idrees, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARION, OH · NPI 1447218292
Verified facts
What the public records show
CMS Open Payments records show Ghulam Idrees, MD received $821.26 in general payments during 2025 across 44 reported records.
Novartis Pharmaceuticals Corporation accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Nuplazid, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuplazid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 509 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $102.95 | 12.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.44 | 10.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.74 | 10.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.52 | 9.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.88 | 7.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.87 | 6.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.06 | 6.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.55 | 6.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.66 | 5.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.92 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.36 | 3.9% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $27.62 | 3.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.52 | 2.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.92 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.16 | 2.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.25 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.57 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.27 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $821.26 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $102.95 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $72.67 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.55 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.94 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.92 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 509 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 160 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
89 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
160 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
509 | 69 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1107 | 226 |
| Furosemide | Furosemide | 910 | 153 |
| Losartan Potassium | Losartan Potassium | 786 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 576 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 94 |
| Potassium Chloride | Potassium Chloride | 522 | 84 |
| Eliquis | Apixaban | 509 | 69 |
| Gabapentin | Gabapentin | 481 | 89 |
| Metformin Hcl | Metformin Hcl | 461 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 82 |
| Omeprazole | Omeprazole | 365 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 344 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 321 | 59 |
| Trazodone Hcl | Trazodone Hcl | 316 | 67 |
| Sertraline Hcl | Sertraline Hcl | 269 | 44 |
| Januvia | Sitagliptin Phosphate | 268 | 25 |
| Lisinopril | Lisinopril | 268 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 57 |
| Carvedilol | Carvedilol | 259 | 55 |
| Donepezil Hcl | Donepezil Hcl | 248 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 243 | 43 |
| Mirtazapine | Mirtazapine | 239 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 236 | 39 |
| Tradjenta | Linagliptin | 236 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 215 | 40 |
| Buspirone Hcl | Buspirone Hcl | 202 | 42 |
| Levetiracetam | Levetiracetam | 186 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 37 |
| Warfarin Sodium | Warfarin Sodium | 171 | 20 |
| Memantine Hcl | Memantine Hcl | 168 | 26 |
| Farxiga | Dapagliflozin Propanediol | 160 | 17 |
| Glipizide | Glipizide | 159 | 31 |
| Prednisone | Prednisone | 156 | 68 |
| Tizanidine Hcl | Tizanidine Hcl | 144 | 30 |
| Jardiance | Empagliflozin | 138 | 12 |
| Allopurinol | Allopurinol | 134 | 30 |
| Gemtesa | Vibegron | 134 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 27 |
| Famotidine | Famotidine | 116 | 33 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 114 | 32 |
| Simvastatin | Simvastatin | 114 | 28 |
| Finasteride | Finasteride | 112 | 18 |
| Xarelto | Rivaroxaban | 111 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 22 |
| Montelukast Sodium | Montelukast Sodium | 107 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 21 |
| Metformin Hcl Er | Metformin Hcl | 95 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 58 |
| Sucralfate | Sucralfate | 91 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 50 |
| Aripiprazole | Aripiprazole | 89 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 40 |
| Linzess | Linaclotide | 89 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 25 |
| Cephalexin | Cephalexin | 86 | 44 |
| Amiodarone Hcl | Amiodarone Hcl | 85 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 84 | 19 |
| Baclofen | Baclofen | 83 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 14 |
| Tramadol Hcl | Tramadol Hcl | 78 | 23 |
| Nystatin | Nystatin | 74 | 40 |
| Alendronate Sodium | Alendronate Sodium | 73 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 45 |
| Spironolactone | Spironolactone | 69 | 23 |
| Midodrine Hcl | Midodrine Hcl | 67 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 11 |
| Lamotrigine | Lamotrigine | 65 | suppressed |
| Ozempic | Semaglutide | 63 | 11 |
| Alprazolam | Alprazolam | 61 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 25 |
| Novolog Flexpen | Insulin Aspart | 53 | 12 |
| Bumetanide | Bumetanide | 51 | 12 |
| Myrbetriq | Mirabegron | 51 | 11 |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Olanzapine | Olanzapine | 50 | suppressed |
| Primidone | Primidone | 48 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 44 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 13 |
| Latanoprost | Latanoprost | 41 | 11 |
| Lorazepam | Lorazepam | 41 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 17 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Vraylar | Cariprazine Hcl | 39 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Lactulose | Lactulose | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Constulose | Lactulose | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 14 |
| Acetic Acid | Acetic Acid | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 26 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 13 |
| Kerendia | Finerenone | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | 12 |
| Azithromycin | Azithromycin | 22 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Clobazam | Clobazam | 20 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 16 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 14 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $821.26 · 44 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AIRSUPRA, BREZTRI, CREON, CeQur Simplicity, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NUPLAZID, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error